CleanupBot (talk | contribs) m →References: clean up, add source tag |
m robot: Update article (please report if you notice any mistake or error in this edit) |
||
| Line 1: | Line 1: | ||
{{Use dmy dates|date=June 2022}} | |||
{{Use Indian English|date=June 2022}} | |||
{{Infobox company | {{Infobox company | ||
| name = Natco Pharma | | name = Natco Pharma | ||
| Line 4: | Line 6: | ||
| logo_size = | | logo_size = | ||
| caption = | | caption = | ||
| type = Public company | | type = [[Public company|Public]] | ||
| genre = | | genre = | ||
| traded_as = {{NSE|NATCOPHARM}} <br /> {{BSE|524816}} | | traded_as = {{NSE|NATCOPHARM}} <br /> {{BSE|524816}} | ||
| Line 10: | Line 12: | ||
| successor = | | successor = | ||
| foundation = 1981 | | foundation = 1981 | ||
| | | founder = VC Nannapaneni | ||
| defunct = | | defunct = | ||
| location_city = [[Hyderabad]] | | location_city = [[Hyderabad]], [[Telangana]] | ||
| location_country = | | location_country = India | ||
| locations = | | locations = | ||
| area_served = Global | | area_served = Global | ||
| Line 20: | Line 22: | ||
| products = | | products = | ||
| services = | | services = | ||
| revenue = | | revenue = {{INRconvert|2155|c}} (FY2021) | ||
| operating_income = | | operating_income = | ||
| net_income = | | net_income = | ||
| Line 27: | Line 29: | ||
| equity = | | equity = | ||
| owner = | | owner = | ||
| num_employees = | | num_employees = | ||
| parent = | | parent = | ||
| divisions = | | divisions = | ||
| Line 33: | Line 35: | ||
| footnotes = | | footnotes = | ||
}} | }} | ||
'''Natco Pharma''' is an Indian multinational [[pharmaceutical]] company based in [[Hyderabad]]. The company manufactures finished dosage formulations [[active pharmaceutical ingredients]] and [[Agricultural science|crop health science]] products, and also provides [[Contract manufacturing organization|contract manufacturing services]].<ref name=":0">{{Cite web |title=Our Business {{!}} Natco Pharma |url=https://www.natcopharma.co.in/our-business/ |access-date=2022-04-25}}</ref> It is a major producer of branded [[oncology]] medicines<ref name="paraiv">{{cite news |title=Natco Pharma lines up 20 'Para IV' products |url=https://www.thehindubusinessline.com/companies/natco-pharma-lines-up-20-para-iv-products/article29408594.ece |accessdate=19 April 2020 |work=The Hindu Business Line}}</ref> and [[hepatitis C]] drugs.<ref name=ladder/> The company specialises in producing complex medicines at affordable prices.<ref>{{Cite news |last=PTI |date=17 December 2020 |title=Natco Pharma launches anti blood clot medication, Rivaroxaban, in India |work=The Economic Times |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-launches-anti-blood-clot-medication-rivaroxaban-in-india/articleshow/79779503.cms?from=mdr |access-date=2022-04-25}}</ref><ref>{{Cite web |last=Akolkar |first=Shrikant |date=9 March 2017 |title=Natco Pharma: Top league player |url=https://www.angelone.in/get-co-pdf/AngelBrokingResearch_NatcoPharma_Inititatingcoverage_090317.pdf |access-date=25 April 2022 |website=Angel One}}</ref> In 2019, Natco launched its crop health sciences division.<ref>{{Cite web |title=Mission & Heritage {{!}} Natco Pharma |url=https://www.natcopharma.co.in/about/mission-heritage/ |access-date=2022-04-25}}</ref><ref>{{Cite web |last=Sridhar |first=G. Naga |date=2020-11-25 |title=Natco Pharma expects agri business to be key growth lever |url=https://www.thehindubusinessline.com/companies/natco-pharma-expects-agri-business-to-be-key-growth-lever/article33175348.ece |access-date=2022-04-24 |website=www.thehindubusinessline.com |language=en}}</ref> | |||
== History == | |||
* In 2003, Natco Pharma launched Veenat, a generic version of [[Novartis AG]]'s anti-cancer drug [[Glivec]]. It won the subsequent patent protection legal battle against Novartis in 2013.<ref name="niche">{{cite news|title=Niche Play|work=Business Today|url=https://www.businesstoday.in/story/vc-nannapaneni-natco-pharma-ceo-best-ceo-business-today-survey-pharmaceutical-industry-hyderabad-based/1/267691.html|accessdate=19 April 2020}}</ref> | |||
* In 2012, Natco Pharma obtained [[compulsory license]] to produce a cheaper and generic version of [[Bayer]]'s anti-cancer medication [[Nexavar]].<ref name="ladder">{{cite news |title=How Natco defied the odds to rise up India's pharma ladder |url=https://www.moneycontrol.com/news/business/companies/how-natco-defied-the-odds-to-rise-up-indias-pharma-ladder-2583413.html |accessdate=19 April 2020 |work=Moneycontrol}}</ref> | |||
* In the United States, it launched [[influenza]] medication [[Tamiflu]] with marketing partner [[Alvogen]], [[multiple sclerosis]] treatment drug [[glatiramer acetate]] in partnership with [[Mylan]], and [[hepatitis C]] drugs under a licensing agreement with [[Gilead Sciences]].<ref name="niche" /> | |||
* In 2015, Natco Pharma started production of [[Sofosbuvir]] in Nepal.<ref>{{Cite web|title=Natco Pharma History {{!}} Natco Pharma Information|url=https://economictimes.indiatimes.com/natco-pharma-ltd/infocompanyhistory/companyid-8305.cms|access-date=2022-02-03|website=The Economic Times|language=en}}</ref> | |||
* In 2016, Natco Pharma launched the first [[Tamiflu]] capsule in the US market.<ref>{{Cite web|title=Bayer cancer drug faces new Nexavar patent problems in India|url=https://www.thepharmaletter.com/article/bayer-cancer-drug-faces-new-nexavar-patent-problems-in-india|access-date=2022-02-03|website=www.thepharmaletter.com}}</ref> | |||
* In 2017, Natco Pharma launched a generic version of [[blood cancer]] drug [[Pomalidomide]] at a 98% discount to the drug's selling price in the United States.<ref>{{cite news |title=Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost |url=https://www.firstpost.com/business/natco-pharma-launches-blood-cancer-drug-priced-rs-5000-20000-down-98-from-us-price-3436186.html |accessdate=31 July 2020 |work=Firstpost |date=10 May 2017}}</ref> | |||
* In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in [[Nellore district]], [[Andhra Pradesh]].<ref>{{cite web | url=https://www.dailyexcelsior.com/natco-pharma-to-invest-rs-100-cr-for-setting-up-agrichemical-facilities-in-andhra/ | title=Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra | date=25 January 2019 }}</ref> | |||
== External links == | |||
* [https://www.natcopharma.co.in/ Official website] | |||
==References== | ==References== | ||
| Line 52: | Line 61: | ||
[[Category:1981 establishments in Andhra Pradesh]] | [[Category:1981 establishments in Andhra Pradesh]] | ||
[[Category:Indian companies established in 1981]] | [[Category:Indian companies established in 1981]] | ||
[[Category:Companies listed on the National Stock Exchange of India]] | |||
[[Category:Companies listed on the Bombay Stock Exchange]] | |||
Revision as of 07:43, 12 June 2022
 | |
| Traded as | NSE: NATCOPHARM BSE: 524816 |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1981 |
| Founder(s) | VC Nannapaneni |
| Headquarters | , India |
Area served | Global |
Key people | VC Nannapaneni (Chairman and MD)[1] Rajeev Nannapaneni (CEO and Vice Chairman)[2] |
| Revenue | ₹2,155 crore (US$300 million) (FY2021) |
| Website | natcopharma.co.in |
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services.[3] It is a major producer of branded oncology medicines[4] and hepatitis C drugs.[5] The company specialises in producing complex medicines at affordable prices.[6][7] In 2019, Natco launched its crop health sciences division.[8][9]
History
- In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[10]
- In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[5]
- In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[10]
- In 2015, Natco Pharma started production of Sofosbuvir in Nepal.[11]
- In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.[12]
- In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.[13]
- In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[14]
External links
References
- ↑ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
- ↑ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
- ↑ "Our Business | Natco Pharma". Retrieved 25 April 2022.
- ↑ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
- ↑ 5.0 5.1 "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
- ↑ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
- ↑ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
- ↑ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
- ↑ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
- ↑ 10.0 10.1 "Niche Play". Business Today. Retrieved 19 April 2020.
- ↑ "Natco Pharma History | Natco Pharma Information". The Economic Times. Retrieved 3 February 2022.
- ↑ "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
- ↑ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost". Firstpost. 10 May 2017. Retrieved 31 July 2020.
- ↑ "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.